



# Contribution of Maternal Immunity to Decreased Rotavirus Vaccine Performance in Low- and Middle-Income Countries

Katayi Mwila,<sup>a</sup> Roma Chilengi,<sup>a,c</sup> Michelo Simuyandi,<sup>a</sup> Sallie R. Permar,<sup>b</sup> Sylvia Becker-Dreps<sup>c</sup>

Centre for Infectious Disease Research in Zambia, Lusaka, Zambia<sup>a</sup>; Department of Pediatrics, Human Vaccine Institute, Duke University, Durham, North Carolina, USA<sup>b</sup>; Department of Family Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA<sup>c</sup>

**ABSTRACT** The role of maternal immunity, received by infants either transplacentally or orally from breast milk, in rotavirus vaccine (RV) performance is evaluated here. Breastfeeding withholding has no effect on vaccine responses, but higher levels of transplacental rotavirus-specific IgG antibody contribute to reduced vaccine seroconversion. The gaps in knowledge on the factors associated with low RV efficacy in low- and middle-income countries (LMIC) remain, and further research is needed to shed more light on these issues.

**KEYWORDS** immunization, low- and middle-income countries, maternal, rotavirus

Despite the progress seen with the global introduction of rotavirus vaccines (RV), diarrhea is still a leading cause of death in children under the age of 5 years, and a substantial proportion of disease cases are still attributable to rotavirus infection. The latest estimates show that approximately 215,000 children die each year from rotavirus-associated diarrhea, and approximately 56% of these deaths are in sub-Saharan Africa (1). The World Health Organization (WHO) recommended the introduction of oral RV into national immunization programs (2), and many countries have heeded this call. As of September 2016, the WHO lists 86 countries as having included RV in their national immunization programs, and 6 more are in the course of doing so in 2016 ([www.who.int/immunization/monitoring\\_surveillance/VaccineIntroStatus.pptx](http://www.who.int/immunization/monitoring_surveillance/VaccineIntroStatus.pptx)). Approximately 50% of the countries in Africa and Asia, over 80% of those in North America, South America, and Australia, and approximately 40% of those in Europe have introduced RV. Following RV introduction, there was a notable reduction in the number of deaths due to diarrhea (1). However, there is consistent evidence from clinical trials that RV have lower efficacies in low- and middle-income countries (LMIC): vaccine efficacies are 80 to 90% in high-income countries (HIC) and 40 to 60% in LMIC (3–8). Indeed, there is growing evidence from vaccine effectiveness studies emerging from the field that in real-life use, vaccine effectiveness is also consistently lower in LMIC (9–12).

In addition to the differences in observed vaccine efficacy and effectiveness, there are also marked differences in vaccine-elicited immunity as reported by various vaccine-elicited antibody titers following rotavirus immunization (13–18). A number of hypotheses have been put forward to explain the differences in efficacy and vaccine-elicited immunity between HIC and LMIC. The hypotheses include (i) maternal factors (such as interference from transplacental antibodies and antibody and nonantibody breast milk components [13, 19–23]), (ii) coadministration with the oral polio vaccine (24–27), (iii) concurrent infection with other enteric pathogens (28), (iv) micronutrient or protein-energy malnutrition (29–31), (v) effects of environmental enteropathy or

Accepted manuscript posted online 9 November 2016

**Citation** Mwila K, Chilengi R, Simuyandi M, Permar SR, Becker-Dreps S. 2017. Contribution of maternal immunity to decreased rotavirus vaccine performance in low- and middle-income countries. *Clin Vaccine Immunol* 24:e00405-16. <https://doi.org/10.1128/CVI.00405-16>.

**Editor** Christopher J. Papasian, UMKC School of Medicine

**Copyright** © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Roma Chilengi, [Roma.Chilengi@cidrz.org](mailto:Roma.Chilengi@cidrz.org), or Sylvia Becker-Dreps, [sbd@unc.edu](mailto:sbd@unc.edu).

dysbiosis of the gut microbiome (32–37), and (vi) host genetic factors (histo-blood group antigens [38, 39]). A better understanding of these factors which decrease the efficacy of RV in LMIC may help to inform interventions to improve efficacy and to further reduce the number of child deaths due to rotavirus disease. This review examines the correlations between maternal immune factors and RV responses and their potential effect on vaccine efficacy.

### **NATURAL ROTAVIRUS INFECTION AND SUBSEQUENT PROTECTION**

Rotavirus has a triple-layered capsid composed of structural proteins (VP2, VP6, and VP7) and protruding spikes that mediate cell binding (VP4); the capsid surrounds the viral RNA-dependent RNA polymerase (VP1), the capping enzyme (VP3), and the viral genome, composed of 11 segments of double-stranded RNA (dsRNA). Rotaviruses occur in at least 8 different species (groups A to H) (40), but only group A to C and H rotaviruses can infect humans, and the majority of cases of human rotavirus disease (acute gastroenteritis) are caused by viruses of group A. Rotaviruses are further classified into G and P subtypes (according to antigenicity and the sequences of VP7 and VP4, respectively), among which rotaviruses of the subtypes G1P[8], G2P[4], G3P[8], G4P[8], G9P[8], and, more recently, G12P[8] cause approximately 90% of all cases of human rotavirus infection and disease (41). A classic cohort study by Velázquez et al. (42) showed that it takes two or more consecutive rotavirus infections before protection from rotavirus-associated disease is achieved.

Rotavirus infections can be blocked by maternal antibodies acquired passively from the placenta and from breast milk. Cord blood has been shown to contain rotavirus-specific IgG, but not other antibody isotypes (43), and concentrations of rotavirus-specific IgG in maternal serum are strongly correlated with concentrations of IgG in infant serum (44). Breastfeeding may protect against naturally occurring rotavirus infection, with protection mediated by rotavirus-specific IgA produced through the gut-mammary gland axis and by the nonspecific glycoproteins lactoferrin and lactadherin (45–48). In fact, it is hypothesized that maternally acquired rotavirus-specific antibodies may bind to the RV strains and thereby block the infant's active response to immunization (49). However, evidence for the protective effect of breastfeeding against rotavirus infection is mixed, with work by Glass et al. (50) and Wobudeya et al. (51) suggesting that breastfeeding does not protect against rotavirus gastroenteritis.

### **VACCINES CURRENTLY AVAILABLE FOR ROTAVIRUS CONTROL**

At present, there are two licensed RV endorsed by the WHO (2): monovalent RV (Rotarix), a live attenuated vaccine derived from a human G1P[8] strain, and pentavalent RV (Rotateq), composed of five human-bovine reassortants expressing G1-G4 VP7s and a P[8] VP4 from a human rotavirus parent strain (4, 5). A third available vaccine is a monovalent live attenuated vaccine (Rotavac) consisting of a human G9P[11] strain, which is currently licensed for use only in India (52). All three are oral vaccines, with the first dose recommended for administration at 6 weeks of age. Oral vaccines are noted for their ease of interference, and it is for this reason that the effect of breast milk on RV is of interest.

### **IN VITRO STUDIES OF POTENTIAL IMMUNE FACTORS THAT BLUNT INFANT ROTAVIRUS VACCINE RESPONSES**

Moon and colleagues assessed breast milk immune factors and their impacts on RV variants *in vitro* (19). Breast milk samples tested in vaccine microneutralization assays revealed that women from India had higher vaccine virus neutralization titers to all three RV than those of women from the United States. Plaque reduction assays were carried out on Indian and U.S. breast milk samples with high neutralizing titers and showed that samples from Indian women caused larger reductions in vaccine titers, corresponding to their neutralizing activity levels (19). Further, the breast milk samples from Indian women had the highest rotavirus-specific IgA titers among samples from women from India and three other countries (United States, Vietnam, and South Korea),

with up to 4-fold differences in median titers. Trang et al. (53) investigated the differences in rotavirus-specific IgA titers in breast milk samples from women from rural and urban settings. They showed that women from rural areas had higher levels of rotavirus-specific IgA in breast milk than those of their urban counterparts.

Nonspecific immune factors in breast milk, including glycoproteins and mucins, may also influence vaccine efficacy and effectiveness by inhibiting the replication of rotavirus (45, 46, 54, 55). Lactoferrin and lactadherin have been shown to reduce rotavirus vaccine strain infectivity in microneutralization assays, and similar results were also seen in plaque reduction assays (20). These results strengthened the hypothesis that non-antibody breast milk components play a role in RV efficacy and effectiveness. By investigating this hypothesis, Moon et al. showed that women from LMIC (India and South Africa) had higher lactoferrin and lactadherin levels than their counterparts from an HIC (United States) (20). Breast milk samples from other LMIC in Africa, Latin America, and Asia should be tested for lactoferrin and lactadherin levels before broader conclusions can be reached.

### **OBSERVATIONAL CLINICAL STUDIES OF MATERNAL IMMUNITY AND ROTAVIRUS VACCINE RESPONSES**

Several observational studies have examined the association between breastfeeding and RV immunogenicity. A case-control study in Germany performed by Adlhoch and colleagues found that children who were exclusively breastfed were less likely to seroconvert (56). In Zambia, higher maternal breast milk IgA titers prior to immunization were associated with a lower frequency of infant seroconversion in response to the monovalent RV. In that study, there was a statistically significant decrease in the percentage of children who seroconverted from the lowest to the highest cumulative breast milk IgA quartile, with seroconversion rates of 71%, 54%, 51%, and 46% (13). Yet a study conducted in Nicaragua did not find an association between rotavirus-specific IgA titers in breast milk on the day of infant immunization and the immunogenicity of the pentavalent RV (22). Further, they did not find an association between the innate antiviral factors in breast milk, including lactoferrin, lactadherin, and tenascin-C, and RV responses (57).

One observational study from Nicaragua found a significant association between high maternal rotavirus-specific IgG titers in serum and the failure to seroconvert in response to the pentavalent RV in infants (22). Similar results were seen in a South African cohort, in which higher levels of prevaccination IgG and IgA were associated with lower immunogenicity of the monovalent RV (23).

### **CLINICAL TRIALS OF ROTAVIRUS VACCINE EFFICACY IN BREASTFED AND NONBREASTFED INFANTS AND INTERVENTIONS TO IMPROVE ROTAVIRUS VACCINE EFFICACY**

Two approaches were used to assess the effect of breastfeeding on infant RV efficacy in clinical trials. The first involved comparisons of RV efficacies in breastfed and bottle-fed infants (58–62). These studies were undertaken predominantly in HIC and found no statistically significant difference in seroconversion frequency between children who were fed formula and those who were breastfed, although numbers of seroconverters tended to be slightly higher for formula-fed children. No such studies have been performed in LMIC, likely because of the high prevalence of breastfeeding as opposed to bottle feeding.

The second area of investigation was withholding of breast milk feeding at the time of vaccination. Clinical trials of breastfeeding withholding at the time of monovalent RV administration have been performed in South Africa, India, and Pakistan (63–66). In these settings, lactating women and their infants were recruited and randomly allocated to groups for withholding of breastfeeding for 1 h (South Africa and Pakistan) or 30 min (India) prior to and after vaccination, while control groups breastfed normally. Despite high compliance of the mothers, none of these studies reported differences in seroconversion rates between infants who had breast milk withheld prior to vaccination and those who did not.

While the clinical trials described above seem to refute the hypothesis that breast milk immunity interferes with RV seroconversion, some additional factors should be considered. The clinical trials that reported no differences in breastfed and formula-fed infants were conducted in HIC, so further investigation of the differences in seroconversion between breastfed and formula-fed infants in LMIC is warranted. Another important consideration is that antibodies or other immune factors may persist in the infant's gastrointestinal tract for longer periods than that during which breastfeeding was withheld in the studies. Research has shown that the infant gastric half-emptying time is between 47 and 56 min (67–69); this means that despite withholding of breast feeding before immunization in the reported trials, the vaccine still may have come into contact with breast milk in the stomach, or perhaps more distally, in the intestines, and therefore may have been neutralized before an immune response could be produced. Addressing this question through studies that withhold breastfeeding would require longer withholding periods that may not be feasible or ethical. To avoid interference of oral RV by breast milk, one potential option may be a shift to parenteral RV in LMIC (70–75).

Transplacentally acquired rotavirus-specific IgG represents one of the proposed factors for reduced infant vaccine efficacy (21, 22), as shown for other pediatric vaccines, such as measles, tetanus, and pneumococcal vaccines (76). The clinical trial of ORV-116E (Rotavac; Bharat Biotech) found that transplacentally acquired rotavirus-specific IgG interfered with seroconversion but that this effect could be overcome by an increase of the vaccine dose (21). Transplacental rotavirus-specific IgG titers are likely higher in LMIC than in HIC, based on differences observed in breast milk (19, 48), possibly due to repeated exposure of mothers to enteric pathogens in LMIC. This work suggests that a higher dose of RV or additional booster doses of RV at a time when transplacental IgG has waned may improve vaccine immunogenicity in LMIC.

### **HIV INFECTION/EXPOSURE AND ITS IMPLICATIONS FOR ROTAVIRUS VACCINE EFFICACY**

Due to the high prevalence of HIV infection in many LMIC, trials have been conducted to assess the efficacy of RV in HIV-positive and HIV-negative children. In these studies, the HIV status of children did not affect their ability to mount an immune response to the vaccine, and no significant adverse reactions have been reported (77–79). A review by Filteau (80) also brings to light the fact that HIV is responsible for significant immune dysfunction, including a reduced ability of HIV-positive pregnant mothers to transfer transplacental antibodies to infants (81, 82). While this may leave children at greater risk for a large number of infections, there may be an unanticipated benefit in the context of vaccines. We postulate here that in LMIC, where maternal antibodies have been noted to potentially interfere with RV seroconversion in infants, the lower level of functional maternal antibodies may in turn render HIV-exposed but -uninfected children more likely to seroconvert, if transplacental antibodies do indeed interfere with vaccine responses. This effect was found in one case-control study conducted in South Africa (83), in which vaccine effectiveness trended higher in HIV-exposed but -uninfected children than in HIV-unexposed children, especially for the 6-week dose, but additional research is needed to formulate a more conclusive association, as this observation was not statistically significant.

### **CONCLUSIONS**

In this review, we summarized reports on associations between immune factors in breast milk as well as transplacental antibodies and infant RV efficacy. We reviewed reports on *in vitro* studies that have shown that both antibody and nonantibody components of breast milk may have an effect on the infectivity of RV strains and therefore may partially contribute to blocking of the immune response of infants. Our review of observational trials showed a general association of higher breast milk rotavirus-specific IgA and transplacentally acquired rotavirus-specific IgG titers with failed seroconversion, while in clinical trials that withheld breast milk at the time of

vaccination it appeared that there was no significant effect on seroconversion of infants. Lastly, we hypothesize that immune dysfunction due to maternal HIV infection may be associated with higher RV effectiveness.

If the association of maternal immunity and vaccine interference is strengthened in LMIC, there are a number of strategies that may improve the infant vaccine response in areas of high rotavirus burden. First, an increase in vaccine dosage is one strategy worth considering to help overcome interference from maternal immune factors. Second, following the successful strategy applied to the measles vaccine, a modified RV schedule or additional doses of vaccine when maternal antibody has waned may improve vaccine responsiveness. In fact, studies of the monovalent RV from Ghana, South Africa, and Bangladesh all suggest a benefit of this strategy (84–86). These studies showed benefits in immunogenicity of delaying the first dose of RV from 6 until 10 weeks of life and adding a third dose of RV either at 14 weeks or at 9 months of age. However, the benefits of these alternative schedules need to be weighed carefully against decreased protection in early infancy, prior to receipt of the first RV dose, as well as potential impacts to vaccine coverage that may result with a change in schedule. Finally, learning from the polio vaccine experience, the switch to a parenteral route would overcome the hypothesized interference by breast milk immune factors (87, 88). While some inactivated parenteral RV candidates have shown promise in animal studies (70, 89), the research and development costs to bring these vaccines to human clinical trials would be substantial. Improving RV efficacy through alterations in dosing, schedule, or administration route may have a major impact on global infant diarrheal disease and its associated mortality.

#### ACKNOWLEDGMENTS

S.B.-D. is supported by the National Institute of Allergy and Infectious Diseases (grant R56AI108515). R.C. is supported by the National Institute of Allergy and Infectious Diseases (grant 5R01AI099601-05).

S.B.-D. receives investigator-initiated research funding from Pfizer. S.R.P. has served as an unpaid consultant for Pfizer.

We gratefully acknowledge Erica Nouri for her editing assistance.

#### REFERENCES

1. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD, World Health Organization—Coordinated Global Rotavirus Surveillance Network. 2016. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000–2013. *Clin Infect Dis* 62(Suppl 2):S96–S105. <https://doi.org/10.1093/cid/civ1013>.
2. WHO. 2013. Rotavirus vaccines WHO position paper—January 2013. *Wkly Epidemiol Rep* 88:49–64.
3. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. 2009. Oral rotavirus vaccines: how well will they work where they are needed most? *J Infect Dis* 200(Suppl):S39–S48. <https://doi.org/10.1086/605035>.
4. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavía-Ruz N, Salmerón J, Rüttimann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzabal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckennooghe A, Clemens R, De Vos B, O’Ryan M, Human Rotavirus Vaccine Study Group. 2006. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. *N Engl J Med* 354:11–22. <https://doi.org/10.1056/NEJMoa052434>.
5. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gøthefors L, Campens D, Karvonen A, Watt JP, O’Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM, Rotavirus Efficacy and Safety Trial (REST) Study Team. 2006. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. *N Engl J Med* 354: 23–33. <https://doi.org/10.1056/NEJMoa052664>.
6. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Anshah NA, Levine MM, Lewis K, Coia ML, Attah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyambane G, Hodgson A, Schödel F, Ciarlet M, Neuzil KM. 2010. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. *Lancet* 376:606–614. [https://doi.org/10.1016/S0140-6736\(10\)60889-6](https://doi.org/10.1016/S0140-6736(10)60889-6).
7. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, Neuzil KM. 2010. Effect of human rotavirus vaccine on severe diarrhea in African infants. *N Engl J Med* 362:289–298. <https://doi.org/10.1056/NEJMoa0904797>.
8. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TPM, Luby SP, Le HT, Coia ML, Lewis K, Rivers SB, Sack DA, Schodell F, Steele AD, Neuzil KM, Ciarlet M. 2010. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. *Lancet (London, England)* 376:615–623. [https://doi.org/10.1016/S0140-6736\(10\)60755-6](https://doi.org/10.1016/S0140-6736(10)60755-6).
9. Beres LK, Tate JE, Njobvu L, Chibwe B, Rudd C, Guffey MB, Stringer JSA, Parashar UD, Chilengi R. 2016. A preliminary assessment of rotavirus vaccine effectiveness in Zambia. *Clin Infect Dis* 62(Suppl 2):S175–S182. <https://doi.org/10.1093/cid/civ1206>.
10. Bar-Zeev N, Jere KC, Bennett A, Pollock L, Tate JE, Nakagomi O, Iturriaga-Gomara M, Costello A, Mwansambo C, Parashar UD, Heyderman RS, French N, Cunliffe NA, Vaccine Effectiveness and Disease Surveillance Programme, Malawi (VACSURV) Consortium. 2016. Population impact and effectiveness of monovalent rotavirus vaccination in urban Malawian children 3 years after vaccine introduction: ecological and case-control analyses. *Clin Infect Dis* 62(Suppl 2):S213–S219. <https://doi.org/10.1093/cid/civ1183>.



11. Gastañaduy PA, Steenhoff AP, Mokomane M, Esona MD, Bowen MD, Jibril H, Pernica JM, Mazhani L, Smieja M, Tate JE, Parashar UD, Goldfarb DM. 2016. Effectiveness of monovalent rotavirus vaccine after programmatic implementation in Botswana: a multisite prospective case-control study. *Clin Infect Dis* 62(Suppl 2):S161–S167. <https://doi.org/10.1093/cid/civ1207>.
12. Armah G, Pringle K, Enweronu-Laryea CC, Ansong D, Mwenda JM, Diamentu SK, Narh C, Lartey B, Binka F, Grytdal S, Patel M, Parashar U, Lopman B. 2016. Impact and effectiveness of monovalent rotavirus vaccine against severe rotavirus diarrhea in Ghana. *Clin Infect Dis* 62(Suppl 2):S200–S207. <https://doi.org/10.1093/cid/ciw014>.
13. Chilengi R, Simuyandi M, Beach L, Mwila K, Becker-Dreps S, Emperador DM, Velasquez DE, Bosomprah S, Jiang B. 2016. Association of maternal immunity with rotavirus vaccine immunogenicity in Zambian infants. *PLoS One* 11:e0150100. <https://doi.org/10.1371/journal.pone.0150100>.
14. Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S, Bouckennooghe A, Neuzil KM, Steele AD. 2012. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. *Vaccine* 30(Suppl 1):A44–A51. <https://doi.org/10.1016/j.vaccine.2011.08.080>.
15. Cunliffe NA, Witte D, Ngwira BM, Todd S, Bostock NJ, Turner AM, Chimpeni P, Victor JC, Steele AD, Bouckennooghe A, Neuzil KM. 2012. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. *Vaccine* 30(Suppl 1):A36–A43. <https://doi.org/10.1016/j.vaccine.2011.09.120>.
16. Narang A, Bose A, Pandit AN, Dutta P, Kang G, Bhattacharya SK, Datta SK, Suryakiran PV, Delem A, Han HH, Bock HL. 2009. Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. *Hum Vaccin* 5:414–419. <https://doi.org/10.4161/hv.5.6.8176>.
17. Armah GE, Breiman RF, Tapia MD, Dallas MJ, Neuzil KM, Binka FN, Sow SO, Ojwando J, Ciarlet M, Steele AD. 2012. Immunogenicity of the pentavalent rotavirus vaccine in African infants. *Vaccine* 30(Suppl 1):A86–A93. <https://doi.org/10.1016/j.vaccine.2011.10.006>.
18. Shin S, Anh DD, Zaman K, Yunus M, Mai le TP, Thiem VD, Azim T, Victor JC, Dallas MJ, Steele AD, Neuzil KM, Ciarlet M. 2012. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. *Vaccine* 30(Suppl 1):A106–A113. <https://doi.org/10.1016/j.vaccine.2011.11.091>.
19. Moon S, Wang Y, Shane AL, Nguyen T, Ray P, Dennehy P, Baek LJ, Parashar UD, Glass RI, Jiang B. 2010. Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. *Pediatr Infect Dis J* 29:919–923. <https://doi.org/10.1097/INF.0b013e3181e232ea>.
20. Moon S, Ray P, Dennehy P, Glass RI. 2013. Differential profiles and inhibitory effect on rotavirus vaccines of nonantibody components in breast milk from mothers in developing and developed countries. *Pediatr Infect Dis J* 32:863–870. <https://doi.org/10.1097/INF.0b013e318290646d>.
21. Appaihgari MB, Glass R, Singh S, Taneja S, Rongsen-Chandola T, Bhandari N, Mishra S, Vrati S. 2014. Transplacental rotavirus IgG interferes with immune response to live oral rotavirus vaccine ORV-116E in Indian infants. *Vaccine* 32:651–656. <https://doi.org/10.1016/j.vaccine.2013.12.017>.
22. Becker-Dreps S, Vilchez S, Velasquez D, Moon S-S, Hudgens MG, Zambrana LE, Jiang B. 2015. Rotavirus-specific IgG antibodies from mothers' serum may inhibit infant immune responses to the pentavalent rotavirus vaccine. *Pediatr Infect Dis J* 34:115–116. <https://doi.org/10.1097/INF.0000000000000481>.
23. Moon S, Groome MJ, Velasquez DE, Parashar UD, Jones S, Koen A, van Niekerk N, Jiang B, Madhi SA. 2016. Prevacination rotavirus serum IgG and IgA are associated with lower immunogenicity of live, oral human rotavirus vaccine in South African infants. *Clin Infect Dis* 62:157–165. <https://doi.org/10.1093/cid/civ828>.
24. Patel M, Steele AD, Parashar UD. 2012. Influence of oral polio vaccines on performance of the monovalent and pentavalent rotavirus vaccines. *Vaccine* 30(Suppl 1):A30–A35. <https://doi.org/10.1016/j.vaccine.2011.11.093>.
25. Zaman K, Sack DA, Yunus M, Arifeen SE, Podder G, Azim T, Luby S, Breiman RF, Neuzil K, Datta SK, Delem A, Suryakiran PV, Bock HL, Bangladeshi Rotavirus Vaccine Study Group. 2009. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. *Vaccine* 27:1333–1339. <https://doi.org/10.1016/j.vaccine.2008.12.059>.
26. Emperador DM, Velasquez DE, Estivariz CF, Lopman B, Jiang B, Parashar U. 2016. Interference of monovalent, bivalent, and trivalent oral poliovirus vaccines on monovalent rotavirus vaccine immunogenicity in rural Bangladesh. *Clin Infect Dis* 62:150–156. <https://doi.org/10.1093/cid/civ807>.
27. Rennels MB. 1996. Influence of breast-feeding and oral poliovirus vaccine on the immunogenicity and efficacy of rotavirus vaccines. *J Infect Dis* 174:S107–S111. [https://doi.org/10.1093/infdis/174.Supplement\\_1.S107](https://doi.org/10.1093/infdis/174.Supplement_1.S107).
28. Petri W, Miller M, Binder HJ, Levine MM, Dillingham R, Guerrant RL. 2008. Enteric infections, diarrhea, and their impact on function and development. *J Clin Invest* 118:1277–1290. <https://doi.org/10.1172/JCI34005>.
29. Perez-Schael I, Salinas B, Tomat M, Linhares AC, Guerrero ML, Ruiz-Palacios GM, Bouckennooghe A, Yazabal JP. 2007. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. *J Infect Dis* 196:537–540. <https://doi.org/10.1086/519687>.
30. Prendergast AJ. 2015. Malnutrition and vaccination in developing countries. *Philos Trans R Soc Lond B Biol Sci* 370:20140141. <https://doi.org/10.1098/rstb.2014.0141>.
31. Colgate ER, Haque R, Dickson DM, Carmolli MP, Mychaleckyj JC, Nayak U, Qadri F, Alam M, Walsh MC, Diehl SA, Zaman K, Petri WA, Kirkpatrick BD. 2016. Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial. *Clin Infect Dis* 63:634–641. <https://doi.org/10.1093/cid/ciw346>.
32. Gilmartin AA, Petri WAJ. 2015. Exploring the role of environmental enteropathy in malnutrition, infant development and oral vaccine response. *Philos Trans R Soc Lond B Biol Sci* 370:20140143. <https://doi.org/10.1098/rstb.2014.0143>.
33. Trehan I, Kelly P, Shaikh N, Manary MJ. 2016. New insights into environmental enteric dysfunction. *Arch Dis Child* 101:741–744. <https://doi.org/10.1136/archdischild-2015-309534>.
34. Keusch GT, Denno DM, Black RE, Duggan C, Guerrant RL, Lavery JV, Nataro JP, Rosenberg IH, Ryan ET, Tarr PI, Ward H, Bhutta Z, Coovadia H, Lima A, Ramakrishna B, Zaidi AKM, Hay Burgess DC, Brewer T. 2014. Environmental enteric dysfunction: pathogenesis, diagnosis, and clinical consequences. *Clin Infect Dis* 59:S207–S212. <https://doi.org/10.1093/cid/ciu485>.
35. Prendergast AJ, Humphrey JH, Mutasa K, Majo FD, Rukobo S, Govha M, Mbuya MNN, Moulton LH, Stoltzfus RJ, Sanitation Hygiene Infant Nutrition Efficacy (SHINE) Trial Team. 2015. Assessment of environmental enteric dysfunction in the SHINE Trial: methods and challenges. *Clin Infect Dis* 61(Suppl 7):S726–S732. <https://doi.org/10.1093/cid/civ848>.
36. Nakaya HI, Bruna-Romero O. 2015. Is the gut microbiome key to modulating vaccine efficacy? *Expert Rev Vaccines* 14:777–779. <https://doi.org/10.1586/14760584.2015.1040395>.
37. Naylor C, Lu M, Haque R, Mondal D, Buonomo E, Nayak U, Mychaleckyj JC, Kirkpatrick B, Colgate R, Carmolli M, Dickson D, van der Klis F, Weldon W, Oberste MS, PROVIDE Study Teams, Ma JZ, Petri WA, Jr. 2015. Environmental enteropathy, oral vaccine failure and growth faltering in infants in Bangladesh. *EBioMedicine* 2:1759–1766. <https://doi.org/10.1016/j.ebiom.2015.09.036>.
38. Nordgren J, Sharma S, Bucardo F, Nasir W, Günaydin G, Ouermi D, Nitiema LW, Becker-Dreps S, Simpore J, Hammarström L, Larson G, Svensson L. 2014. Both Lewis and secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner. *Clin Infect Dis* 59:1567–1573. <https://doi.org/10.1093/cid/ciu633>.
39. Coulson BS. 2015. Expanding diversity of glycan receptor usage by rotaviruses. *Curr Opin Virol* 15:90–96. <https://doi.org/10.1016/j.coviro.2015.08.012>.
40. Matthijssens J, Otto PH, Ciarlet M, Desselberger U, Van Ranst M, Johne R. 2012. VP6-sequence-based cutoff values as a criterion for rotavirus species demarcation. *Arch Virol* 157:1177–1182. <https://doi.org/10.1007/s00705-012-1273-3>.
41. Santos N, Hoshino Y. 2005. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. *Rev Med Virol* 15:29–56. <https://doi.org/10.1002/rmv.448>.
42. Velázquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, Glass RI, Estes MK, Pickering LK, Ruiz-Palacios GM. 1996. Rotavirus infections in infants as protection against subsequent infections. *N Engl J Med* 335:1022–1028. <https://doi.org/10.1056/NEJM199610033351404>.

43. McLean B, Holmes IH. 1980. Transfer of antirotaviral antibodies from mothers to their infants. *J Clin Microbiol* 12:320–325.
44. Hjelt K, Grauballe PC, Nielsen OH, Schiøtz P, Krasilnikoff PA. 1985. Rotavirus antibodies in the mother and her breast-fed infant. *J Pediatr Gastroenterol Nutr* 4:414–420. <https://doi.org/10.1097/00005176-198506000-00016>.
45. Superti F, Ammendolia MG, Valenti P, Seganti L. 1997. Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte like cell line HT-29. *Med Microbiol Immunol* 186:83–91. <https://doi.org/10.1007/s004300050049>.
46. Newburg DS, Peterson JA, Ruiz-Palacios GM, Matson DO, Morrow AL, Shults J, Guerrero ML, Chaturvedi P, Newburg SO, Scallan CD, Taylor MR, Ceriani RL, Pickering LK. 1998. Role of human-milk lactadherin in protection against symptomatic rotavirus infection. *Lancet* 351:1160–1164. [https://doi.org/10.1016/S0140-6736\(97\)10322-1](https://doi.org/10.1016/S0140-6736(97)10322-1).
47. Asensi MT, Martinez-Costa C, Buesa J. 2006. Anti-rotavirus antibodies in human milk: quantification and neutralizing activity. *J Pediatr Gastroenterol Nutr* 42:560–567. <https://doi.org/10.1097/01.mpg.0000221892.59371.b3>.
48. Novak D, Svennerholm AM. 2015. A comparison of seasonal variations in rotavirus antibodies in the breast milk of Swedish and Bangladeshi mothers. *Acta Paediatr* 104:247–251. <https://doi.org/10.1111/apa.12841>.
49. Chan J, Nirwati H, Triasih R, Bogdanovic-Sakran N, Soenarto Y, Hakimi M, Duke T, Buttery JP, Bines JE, Bishop RF, Kirkwood CD, Danchin MD. 2011. Maternal antibodies to rotavirus: could they interfere with live rotavirus vaccines in developing countries? *Vaccine* 29:1242–1247. <https://doi.org/10.1016/j.vaccine.2010.11.087>.
50. Glass RI, Stoll BJ, Wyatt RG, Hoshino Y, Banu H, Kapikian AZ. 1986. Observations questioning a protective role for breast-feeding in severe rotavirus diarrhea. *Acta Paediatr Scand* 75:713–718. <https://doi.org/10.1111/j.1651-2227.1986.tb10279.x>.
51. Wobudeya E, Bachou H, Karamagi CK, Kalyango JN, Mutebi E, Wamani H. 2011. Breastfeeding and the risk of rotavirus diarrhea in hospitalized infants in Uganda: a matched case control study. *BMC Pediatr* 11:17. <https://doi.org/10.1186/1471-2431-11-17>.
52. Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S, Goyal N, Kawade A, Kang G, Rathore SS, Juvekar S, Muliylil J, Arya A, Shaikh H, Abraham V, Vrati S, Proschan M, Kohberger R, Thiry G, Glass R, Greenberg HB, Curlin G, Mohan K, Harshavardhan GV, Prasad S, Rao TS, Boslego J, Bhan MK, India Rotavirus Vaccine Group. 2014. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. *Lancet* 383:2136–2143. [https://doi.org/10.1016/S0140-6736\(13\)62630-6](https://doi.org/10.1016/S0140-6736(13)62630-6).
53. Trang NV, Braeckman T, Lernout T, Hau VTB, Anh LTK, Luan LT, Van Damme P, Anh DD. 2014. Prevalence of rotavirus antibodies in breast milk and inhibitory effects to rotavirus vaccines. *Hum Vaccin Immunother* 10:3681–3687. <https://doi.org/10.4161/21645515.2014.980204>.
54. Yolken RH, Peterson JA, Vonderfecht SL, Fouts ET, Midthun K, Newburg DS. 1992. Human milk mucin inhibits rotavirus replication and prevents experimental gastroenteritis. *J Clin Invest* 90:1984–1991. <https://doi.org/10.1172/JCI116078>.
55. Kvistgaard AS, Palleen LT, Arias CF, López S, Petersen TE, Heegaard CW, Rasmussen JT. 2004. Inhibitory effects of human and bovine milk constituents on rotavirus infections. *J Dairy Sci* 87:4088–4096. [https://doi.org/10.3168/jds.S0022-0302\(04\)73551-1](https://doi.org/10.3168/jds.S0022-0302(04)73551-1).
56. Adlhoch C, Hoehne M, Littmann M, Marques AM, Lerche A, Dehnert M, Eckmanns T, Wichmann O, Koch J. 2013. Rotavirus vaccine effectiveness and case-control study on risk factors for breakthrough infections in Germany, 2010–2011. *Pediatr Infect Dis J* 32:e82–e89. <https://doi.org/10.1097/INF.0b013e3182720b71>.
57. Becker-Dreps S, Choi WS, Stamper L, Vilchez S, Velasquez DE, Moon S, Huddgens MG, Jiang B, Permar SR. 17 November 2015. Innate immune factors in mothers' breast milk and their lack of association with rotavirus vaccine immunogenicity in Nicaraguan infants. *J Pediatr Infect Dis Soc* 2015:piv076.
58. Vesikari T, Prymula R, Schuster V, Tejedor J-C, Cohen R, Bouckennooghe A, Damaso S, Han HH. 2012. Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants. *Pediatr Infect Dis J* 31:509–513. <https://doi.org/10.1097/INF.0b013e3182489cac>.
59. Pichichero ME, Losonsky GA, Rennels MB, Disney FA, Green JL, Francis AB, Marsocci SM. 1990. Effect of dose and a comparison of measures of vaccine take for oral rhesus rotavirus vaccine. *Pediatr Infect Dis J* 9:339–344. <https://doi.org/10.1097/00006454-199005000-00007>.
60. Goveia MG, DiNubile MJ, Dallas MJ, Heaton PM, Kuter BJ, REST Study Team. 2008. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. *Pediatr Infect Dis J* 27:656–658. <https://doi.org/10.1097/INF.0b013e318168d29e>.
61. Pichichero ME. 1990. Effect of breast-feeding on oral rhesus rotavirus vaccine seroconversion: a metaanalysis. *J Infect Dis* 162:753–755. <https://doi.org/10.1093/infdis/162.3.753>.
62. Glass RI, Ing DJ, Stoll BJ, Ing RT. 1991. Immune response to rotavirus vaccines among breast-fed and nonbreast-fed children. *Adv Exp Med Biol* 310:249–254. [https://doi.org/10.1007/978-1-4615-3838-7\\_33](https://doi.org/10.1007/978-1-4615-3838-7_33).
63. Ali A, Kazi AM, Cortese MM, Fleming JA, Moon S, Parashar UD, Jiang B, McNeal MM, Steele D, Bhutta Z, Zaidi AKM. 2015. Impact of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine—a randomized trial. *PLoS One* 10:e0127622. <https://doi.org/10.1371/journal.pone.0127622>.
64. Groome MJ, Moon S-S, Velasquez D, Jones S, Koen A, van Niekerk N, Jiang B, Parashar UD, Madhi SA. 2014. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. *Bull World Health Organ* 92:238–245. <https://doi.org/10.2471/BLT.13.128066>.
65. Rongsen-Chandola T, Strand TA, Goyal N, Flem E, Rathore SS, Arya A, Winje BA, Lazarus R, Shanmugasundaram E, Babji S, Sommerfelt H, Vainio K, Kang G, Bhandari N. 2014. Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants. *Vaccine* 32(Suppl 1):A134–A139. <https://doi.org/10.1016/j.vaccine.2014.04.078>.
66. Ali A, Kazi AM, Cortese MM, Fleming JA, Moon S, Parashar UD, Jiang B, McNeal MM, Steele D, Bhutta Z, Zaidi AKM. 2015. Correction: impact of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine—a randomized trial. *PLoS One* 10:e0145568. <https://doi.org/10.1371/journal.pone.0145568>.
67. Billeaud C, Guillet J, Sandler B. 1990. Gastric emptying in infants with or without gastro-oesophageal reflux according to the type of milk. *Eur J Clin Nutr* 44:577–583.
68. Cavkll B. 1981. Gastric emptying in infants fed human milk or infant formula. *Acta Paediatr* 70:639–641. <https://doi.org/10.1111/j.1651-2227.1981.tb05760.x>.
69. Van Den Driessche M, Peeters K, Marien P, Ghooys Y, Devlieger H, Veereman-Wauters G. 1999. Gastric emptying in formula-fed and breast-fed infants measured with the <sup>13</sup>C-octanoic acid breath test. *J Pediatr Gastroenterol Nutr* 29:46–51. <https://doi.org/10.1097/00005176-199907000-00013>.
70. Jiang B, Wang Y, Saluzzo JF, Barger K, Frachette MJ, Glass RI. 2008. Immunogenicity of a thermally inactivated rotavirus vaccine in mice. *Hum Vaccin* 4:143–147. <https://doi.org/10.4161/hv.4.2.5263>.
71. Svennerholm AM, Steele D. 2004. Microbial-gut interactions in health and disease. *Progress in enteric vaccine development*. *Best Pract Res Clin Gastroenterol* 18:421–445. <https://doi.org/10.1016/j.bpg.2003.11.004>.
72. Holmgren J, Svennerholm AM. 2012. Vaccines against mucosal infections. *Curr Opin Immunol* 24:343–353. <https://doi.org/10.1016/j.coi.2012.03.014>.
73. Wen X, Cao D, Jones RW, Hoshino Y, Yuan L. 2015. Tandem truncated rotavirus VP8\* subunit protein with T cell epitope as non-replicating parenteral vaccine is highly immunogenic. *Hum Vaccin Immunother* 11:2483–2489. <https://doi.org/10.1080/21645515.2015.1054583>.
74. Wen X, Wen K, Cao D, Li G, Jones RW, Li J, Szu S, Hoshino Y, Yuan L. 2014. Inclusion of a universal tetanus toxoid CD4(+) T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus DeltaVP8\* subunit parenteral vaccines. *Vaccine* 32:4420–4427. <https://doi.org/10.1016/j.vaccine.2014.06.060>.
75. Lappalainen S, Pastor AR, Malm M, Lopez-Guerrero V, Esquivel-Guadarrama F, Palomares LA, Vesikari T, Blazevic V. 2015. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine. *Arch Virol* 160:2075–2078. <https://doi.org/10.1007/s00705-015-2461-8>.
76. Niewiesk S. 2014. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. *Front Immunol* 5:446. <https://doi.org/10.3389/fimmu.2014.00446>.
77. Groome MJ, Madhi SA. 2012. Five-year cohort study on the burden of hospitalisation for acute diarrhoeal disease in African HIV-infected and HIV-uninfected children: potential benefits of rotavirus vaccine. *Vaccine* 30(Suppl 1):A173–A178. <https://doi.org/10.1016/j.vaccine.2011.08.004>.
78. Steele AD, Madhi SA, Louw CE, Bos P, Tumbo JM, Werner CM, Bicer C, De Vos B, Delem A, Han HH. 2011. Safety, reactogenicity, and immunoge-

- nicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. *Pediatr Infect Dis J* 30:125–130. <https://doi.org/10.1097/INF.0b013e3181f42db9>.
79. Obaro SK, Pugatch D, Luzuriaga K. 2004. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. *Lancet Infect Dis* 4:510–518. [https://doi.org/10.1016/S1473-3099\(04\)01106-5](https://doi.org/10.1016/S1473-3099(04)01106-5).
  80. Filteau S. 2009. The HIV-exposed, uninfected African child. *Trop Med Int Health* 14:276–287. <https://doi.org/10.1111/j.1365-3156.2009.02220.x>.
  81. de Moraes-Pinto MI, Almeida ACM, Kenj G, Filgueiras TE, Tobias W, Santos AMN, Carneiro-Sampaio MMS, Farhat CK, Milligan PJM, Johnson PM, Hart CA. 1996. Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. *J Infect Dis* 173:1077–1084. <https://doi.org/10.1093/infdis/173.5.1077>.
  82. Gaensbauer JT, Rakhola JT, Onyango-Makumbi C, Mubiru M, Westcott JE, Krebs NF, Asturias EJ, Fowler MG, McFarland E, Janoff EN. 2014. Impaired *Haemophilus influenzae* type b transplacental antibody transmission and declining antibody avidity through the first year of life represent potential vulnerabilities for HIV-exposed but -uninfected infants. *Clin Vaccine Immunol* 21:1661–1667. <https://doi.org/10.1128/CVI.00356-14>.
  83. Groome MJ, Page N, Cortese MM, Moyes J, Zar HJ, Kapongo CN, Mulligan C, Diedericks R, Cohen C, Fleming JA, Seheri M, Mphahlele J, Walaza S, Kahn K, Chhagan M, Steele AD, Parashar UD, Zell ER, Madhi SA. 2014. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. *Lancet Infect Dis* 14:1096–1104. [https://doi.org/10.1016/S1473-3099\(14\)70940-5](https://doi.org/10.1016/S1473-3099(14)70940-5).
  84. Armah G, Lewis KDC, Cortese MM, Parashar UD, Anshah A, Gazley L, Victor JC, McNeal MM, Binka F, Steele D, Steele AD. 2016. A randomized controlled trial of the impact of alternative dosing schedules on the immune response to human rotavirus vaccine in rural Ghanaian infants. *J Infect Dis* 213:1678–1685. <https://doi.org/10.1093/infdis/jiw023>.
  85. Steele AD, De Vos B, Tumbo J, Reynders J, Scholtz F, Bos P, de Beer MC, Van der Merwe CF, Delem A. 2010. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. *Vaccine* 28:6542–6548. <https://doi.org/10.1016/j.vaccine.2008.08.034>.
  86. Zaman K, Fleming JA, Victor JC, Yunus M, Bari TIA, Azim T, Rahman M, Mowla SMN, Bellini WJ, McNeal M, Icenogle JP, Lopman B, Parashar U, Cortese MM, Steele AD, Neuzil KM. 2016. Noninterference of rotavirus vaccine with measles-rubella vaccine at 9 months of age and improvements in antirotavirus immunity: a randomized trial. *J Infect Dis* 213:1686–1693. <https://doi.org/10.1093/infdis/jiw024>.
  87. John J, Giri S, Karthikeyan AS, Iturriza-Gomara M, Mulyij J, Abraham A, Grassly NC, Kang G. 2014. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. *Lancet* 384:1505–1512. [https://doi.org/10.1016/S0140-6736\(14\)60934-X](https://doi.org/10.1016/S0140-6736(14)60934-X).
  88. Sutter RW, Bahl S, Deshpande JM, Verma H, Ahmad M, Venugopal P, Rao JV, Agarkhedkar S, Lalwani SK, Kunwar A, Sethi R, Takane M, Mohanty L, Chatterjee A, John TJ, Jafari H, Aylward RB. 2015. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. *Lancet* 386:2413–2421. [https://doi.org/10.1016/S0140-6736\(15\)00237-8](https://doi.org/10.1016/S0140-6736(15)00237-8).
  89. Wan Y, Azevedo M, Saif LJ, Gentsch JR, Glass RI, Jiang B. 2010. Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. *Vaccine* 28:5432–5436. <https://doi.org/10.1016/j.vaccine.2010.06.006>.